A Phase I/II, Open Label, Multicenter, Pilot Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacodynamics of FFP104 in Subjects Previously Diagnosed With Primary Biliary Cirrhosis (PBC)
Phase of Trial: Phase I/II
Latest Information Update: 25 Mar 2019
Price : $35 *
At a glance
- Drugs FFP 104 (Primary)
- Indications Biliary cirrhosis
- Focus Adverse reactions
- Sponsors FF Pharma
- 22 Mar 2019 This trial was discontinued in United Kingdom (end date: 2017-06-23), according to European Clinical Trials Database.
- 31 Aug 2018 Biomarkers information updated
- 29 Sep 2016 This study has been discontinued in Netherlands as per European Clinical Trials Database record.